I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $46.03M |
||||||
Company | Location | Date | Amt. (M) | Details |
||
Bioheart Inc. | Fort Lauderdale, Fla. | 2/28 | $11 | Bioheart raised $11M in its first round of venture financing led by Tyco International Ltd.'s venture capital unit, Tyco Ventures |
||
Curacyte AG | Munich, Germany | 2/8 | EUR7 US$6.5 | Curacyte raised US$6.5M in a seed round of capital financing led by TVM Techno Venture Management GmbH; it included a consortium of European life sciences investors |
||
Quorex Pharmaceuticals Inc. | Carlsbad, Calif. | 2/27 | $18.5 | Quorex raised $18.5M in a Series B financing led by Prism Venture Partners; other investors were Johnson & Johnson Development Corp., Tullis-Dickerson & Co. Inc., IngleWood Ventures, China Development Industrial Bank and Pacific Growth Equities Inc. |
||
Replicor Inc. | Montreal | 2/2 | C$2.6 US$1.73 | Replicor completed a private placement grossing US$1.73M |
||
Zeptosens AG | Witterswil, Switzerland | 2/27 | CHF14 US$8.3 | Zeptosens raised US$8.3M in a second-round financing led by TVM Techno Venture Management; Swiss Life Private Equity Partners also participated, as well as private investors |
||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $16.5M |
||||||
Company (Symbol)# | Partner (Symbol; Country) | Amt. (M) | Triggering Event | Details (Date) |
||
Axys Pharmaceuticals Inc. (AXPH) | Merck & Co. Inc. | $1.5 | Milestone payment | Axys received a $1.5M payment for meeting a milestone in the development of a compound that could potentially treat osteoporosis (2/8) |
||
EpiGenesis Pharmaceuticals Inc.* | Chiesi Farmaceutici SpA (Italy) | $15 | Milestone payment | Chiesi paid EpiGenesis $15M associated with the European nonexclusive licensing deal for EPI-2010 (2/28) |
||
Infigen Inc.* | Novartis Pharma AG (Switzerland) | ND | Milestone payment | Infigen achieved its second milestone in its collaboration with Novartis for the production of transgenic cloned pigs using Infigen's nuclear transfer-based cloning system (2/26) |
||
|
Notes: |
||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||||
*Denotes privately held company. ND = not disclosed |
||||||
